Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 3Completed 3Withdrawn 2Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Astrocytoma 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × PT-100 dipeptide × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00303940 2012-03-15

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Familial ependymoma, Ovarian Germ Cell Cancer, Astrocytoma, Kidney Neoplasms, Liver Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡